Eli Lilly’s Alzheimer’s drug fails in late-stage trial, dashing hopes

(By Damian Garde for STAT)

An investigational Alzheimer’s treatment from Eli Lilly failed to slow the progression of the memory-destroying disease in a late-stage trial, marking another setback in a field that has long bedeviled the drug industry. Continue reading article here…

stat-logo

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.